Eli Lilly and Company (LLY.F)
| Previous Close | 708.30 |
| Open | 698.00 |
| Bid | 684.10 x 30000 |
| Ask | 685.20 x 30000 |
| Day's Range | 679.30 - 700.00 |
| 52 Week Range | 384.00 - 742.80 |
| Volume | |
| Avg. Volume | 647 |
| Market Cap | 651.02B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 112.44 |
| EPS (TTM) | 6.07 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | 4.75 (0.67%) |
| Ex-Dividend Date | Feb 14, 2024 |
| 1y Target Est | N/A |
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
